Advertisement

Topics

Green light for Celgene’s targeted AML drug

06:40 EDT 2 Aug 2017 | PharmaTimes

US regulators have issued a green light for Celgene and Agios’ Idhifa, the first and only targeted treatment for adult patients with relapsed/refractory acute myeloid leukaemia and an isocitrate dehydrogenase-2 mutation.

Original Article: Green light for Celgene’s targeted AML drug

NEXT ARTICLE

More From BioPortfolio on "Green light for Celgene’s targeted AML drug"

Quick Search
Advertisement